SVB Securities analyst Andrew Berens maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $65.00. The company’s shares closed last Tuesday at $56.29.
According to TipRanks.com, Berens has 0 stars on 0-5 stars ranking scale with an average return of -5.0% and a 45.4% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.
Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $81.75, representing a 63.5% upside. In a report released yesterday, Piper Sandler also maintained a Hold rating on the stock with a $59.00 price target.
Blueprint Medicines’ market cap is currently $3.35B and has a P/E ratio of -4.74.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in May 2022, Nicholas Lydon, a Director at BPMC bought 10,909 shares for a total of $213,053.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC: